Investigating the role played by inflammation in the development of BRAFV600E-driven colorectal cancer

Read full text Summarise with VIRAT
Authors: Caleb Green
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Colorectal cancer (CRC) is the third most common malignancy worldwide and the leading cause of cancer-related mortality in Western populations. Approximately 70% of CRCs develop through the adenoma-carcinoma sequence driven by adenomatous polyposis coli (APC) mutation. ~15% arise via the serrated neoplasia pathway, characterised by serrated histology, V-Raf murine sarcoma viral oncogene (BRAF) mutations and microsatellite instability. Inflammation is critical for CRC initiation and progression; however, the pro-tumorigenic role of specific inflammatory pathways remain undefined.In-house RNA-sequencing of a genetically engineered mouse model with inducible BrafV600E expression revealed significant suppression of immune signatures, including interferon-γ (IFN-γ) and interleukin-6, in the small intestine (SI). Paradoxically, gene set enrichment analysis of human sessile serrated lesions, commonly harbouring BRAFV600E mutations, demonstrated upregulation of these signatures. Tumour formation in our model is infrequent and delayed, which we hypothesise reflects the absence of a pro-inflammatory environment.This study aims to define the relationship between BrafV600E and inflammatory signalling using proteomic and spatial transcriptomic analysis of murine tissue following short- and long-term oncogene induction. Mouse intestinal organoids (MIOs) will be employed to investigate cell-autonomous interactions between BrafV600E epithelium and inflammatory pathways. Complementary transcriptomic analysis of human datasets will characterise inflammatory signalling across the premalignant and malignant stages of human CRC.In our model, prolonged BrafV600E expression (6 months) abolished STAT1 and STAT3 phosphorylation in vivo, confirmed histologically in SI tissue. Short-term induction of BrafV600E MIOs in vitro, also showed comparable STAT1 and STAT3 activation regardless of genotype. Strikingly, pSTAT3 expression was restored in BrafV600E carcinomas, implicating its reactivation in tumorigenesis. Transcriptomic analyses revealed sustained suppression of inflammatory signalling in mutant SI up to 6 months, accompanied by tissue-specific upregulation in the colon, consistent with progressive inflammation observed in human serrated neoplasms. Attempts to assess BrafV600E-mediated protection against IFN-γ-mediated apoptosis in vitro were inconclusive.Overall, these data uncover a tissue-specific relationship between BrafV600E and inflammation, implicating inflammatory signalling as a driver of serrated tumorigenesis and a potential therapeutic target in CRC prevention.

Fields of Study & Subjects

Colorectal Cancer Treatments and Studies Genetic factors in colorectal cancer Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
University of Leicester
Publication date
25 March 2026
Language
EN
Document type
Thesis